CRXT Key Statistics, Chart & Performance
The current stock price of CRXT is 0.099 USD. In the past month the price decreased by -66.21%.
CRXT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.13 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.98 | 499.57B | ||
| MRK | MERCK & CO. INC. | 12.08 | 264.21B | ||
| PFE | PFIZER INC | 7.87 | 143.17B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.15 | 108.83B | ||
| ZTS | ZOETIS INC | 19.86 | 55.49B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.45 | 22.43B | ||
| VTRS | VIATRIS INC | 5.35 | 14.35B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.46 | 11.19B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.01B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.56B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.43B |
Related stock screener links
About CRXT
Company Profile
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company, which engages in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is headquartered in Northbrook, Illinois and currently employs 16 full-time employees. The company went IPO on 2020-12-17. The firm is focused on the commercialization of JATENZO, an oral T-replacement, or T-replacement therapy (TRT). The Company’s lead product, JATENZO, an androgen indicated for T-replacement therapy to treat adult men with hypogonadism due to certain medical conditions. In addition, JATENZO focuses on the classic signs and symptoms associated with hypogonadism, including psychosexual symptoms, body mass index, fat mass and bone mineral density. The firm plans to focused on the development and commercialization of T and metabolic therapies for men and women.
Company Info
CLARUS THERAPEUTICS HOLDINGS
555 Skokie Boulevard, Suite 340
Northbrook ILLINOIS US
CEO: Joseph Hernandez
Employees: 16
Phone: 16463030737.0
CLARUS THERAPEUTICS HOLDINGS / CRXT FAQ
What does CRXT do?
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company, which engages in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is headquartered in Northbrook, Illinois and currently employs 16 full-time employees. The company went IPO on 2020-12-17. The firm is focused on the commercialization of JATENZO, an oral T-replacement, or T-replacement therapy (TRT). The Company’s lead product, JATENZO, an androgen indicated for T-replacement therapy to treat adult men with hypogonadism due to certain medical conditions. In addition, JATENZO focuses on the classic signs and symptoms associated with hypogonadism, including psychosexual symptoms, body mass index, fat mass and bone mineral density. The firm plans to focused on the development and commercialization of T and metabolic therapies for men and women.
Can you provide the latest stock price for CLARUS THERAPEUTICS HOLDINGS?
The current stock price of CRXT is 0.099 USD. The price decreased by -36.94% in the last trading session.
Does CLARUS THERAPEUTICS HOLDINGS pay dividends?
CRXT does not pay a dividend.
What is the ChartMill rating of CLARUS THERAPEUTICS HOLDINGS stock?
CRXT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting CRXT stock to perform?
9 analysts have analysed CRXT and the average price target is 3.06 USD. This implies a price increase of 2990.91% is expected in the next year compared to the current price of 0.099.
Can you provide the sector and industry classification for CLARUS THERAPEUTICS HOLDINGS?
CLARUS THERAPEUTICS HOLDINGS (CRXT) operates in the Health Care sector and the Pharmaceuticals industry.
CRXT Technical Analysis
CRXT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CRXT. CRXT may be in some trouble as it scores bad on both profitability and health.
CRXT Financial Highlights
Over the last trailing twelve months CRXT reported a non-GAAP Earnings per Share(EPS) of -1.27. The EPS increased by 43.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -193% | ||
| ROA | -66.68% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CRXT Forecast & Estimates
9 analysts have analysed CRXT and the average price target is 3.06 USD. This implies a price increase of 2990.91% is expected in the next year compared to the current price of 0.099.
For the next year, analysts expect an EPS growth of 87.39% and a revenue growth 35.11% for CRXT